Last reviewed · How we verify
Japanese Encephalitis Vaccine, Live
At a glance
| Generic name | Japanese Encephalitis Vaccine, Live |
|---|---|
| Sponsor | Liaoning Chengda Biotechnology CO., LTD |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis (PHASE4)
- Flavivirus Cross-priming Potential of IMOJEV (NA)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects. (PHASE1)
- Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity (NA)
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity (PHASE2)
- Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province (PHASE4)
- Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: